Ra pharmaceuticals, inc. (RARX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Revenue

3,000

2,500

-

4,928

4,094

4,830

Operating expenses:
Research and development

82,642

54,449

45,251

27,928

15,217

10,016

General and administrative

27,337

14,439

9,778

5,024

2,233

1,924

Total operating expenses

109,979

68,888

55,029

32,952

17,450

11,940

Loss from operations

-106,979

-66,388

-55,029

-28,024

-13,356

-7,110

Other income (expense):
Interest income

4,314

1,464

645

109

-

-

Interest expense with related parties

-

-

-

-

159

-

Loss on debt extinguishment with related parties

-

-

-

-

-602

-

Other expense, net

-23

-38

-74

-967

155

1,607

Total other income (expense), net

4,291

1,426

571

-858

-606

1,607

Loss from operations before benefit from income taxes

-102,688

-64,962

-54,458

-28,882

-13,962

-5,503

Benefit from income taxes

-

-19

-19

-18

-19

-27

Net loss

-102,688

-64,943

-54,439

-28,864

-13,943

-5,476

Gain on extinguishment of redeemable convertible preferred shares

-

-

-

-

1,673

-

Net loss attributable to common stockholders

-

-

-

-28,864

-12,270

-5,476

Net loss per share - basic and diluted (in dollars per share)

-2.31

-2.06

-2.41

-6.98

-24.68

-12.46

Weighted average number of common shares outstanding - basic and diluted (in shares)

44,363

31,542

22,591

4,135

497

439